☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
blenrep
GSK's Blenrep (belantamab mafodotin) Receives EC's Approval for R/R Multiple Myeloma
August 27, 2020
GSK's Blenrep (belantamab mafodotin-blmf) Receives the US FDA's Approval as a Monotherapy Treatment for Multiple Myeloma
August 6, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.